Brandon Imber, MD, MS

Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:

• Employment: Memorial Sloan Kettering Cancer Center:Assistant Attending Radiation Oncologist:Employee
• Compensation: Telix Pharmaceuticals: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: November 2022 ;GT Medical Technologies: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: to present ;AstraZeneca: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Bayer: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Kazia Therapeutics: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Novartis: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;AstraZeneca: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Bayer: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Kazia Therapeutics: Research Grants, Research Funding,
• Ownership: none
• Leadership: none

Presentation(s):

• 204 - Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome

  Monday, September 30, 2024
  10:55 AM – 11:05 AM ET

• 256 - A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort

  Monday, September 30, 2024
  5:40 PM – 5:50 PM ET

• 1094 - Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations

  Tuesday, October 1, 2024
  5:45 PM – 5:50 PM ET

• QP 21 - Heme 4:The Power Duo: CAR T Cells and Radiotherapy in Tandem

  Wednesday, October 2, 2024
  8:00 AM – 9:00 AM ET